117068-71-0Relevant articles and documents
A FACILE SYNTHESIS OF BROMO-2-ALKOXYPYRIDINES
Shiao, Min-Jen,Tarng, Kai-Yih
, p. 819 - 824 (1990)
Several bromo-2-methoxypyridines 2a-2e and bromo-2-benzyloxypyridines 2a'-2e' were synthesised by the reaction of bromo-substituted 2-pyridones 1 which were reacted with alkyl halides in the presence of silver carbonate in benzene.
Mild and Regioselective N-Alkylation of 2-Pyridones in Water
Hao, Xin,Xu, Zhongmiao,Lu, Hongfu,Dai, Xuedong,Yang, Ting,Lin, Xichen,Ren, Feng
supporting information, p. 3382 - 3385 (2015/07/28)
A mild and regioselective N-alkylation reaction of 2-pyridones in water has been developed. Tween 20 (2% w/w) was added to create a micellar system for improved solubility of starting materials, which leads to enhanced reaction rates. The protocol demonstrated a wide substrate scope with good isolated yields (40-94%) for all of the 24 examples evaluated. High regioselectivity favoring N-alkylation over O-alkylation was observed for benzyl halides (>5:1), primary alkyl halides (>6:1), and bulky and less reactive secondary alkyl halides (>2.4:1).
Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
Pei, Zhonghua,Blackwood, Elizabeth,Liu, Lichuan,Malek, Shiva,Belvin, Marcia,Koehler, Michael F. T.,Ortwine, Daniel F.,Chen, Huifen,Cohen, Frederick,Kenny, Jane R.,Bergeron, Philippe,Lau, Kevin,Ly, Cuong,Zhao, Xianrui,Estrada, Anthony A.,Truong, Tom,Epler, Jennifer A.,Nonomiya, Jim,Trinh, Lan,Sideris, Steve,Lesnick, John,Bao, Linda,Vijapurkar, Ulka,Mukadam, Sophie,Tay, Suzanne,Deshmukh, Gauri,Chen, Yung-Hsiang,Ding, Xiao,Friedman, Lori S.,Lyssikatos, Joseph P.
supporting information, p. 103 - 107 (2013/02/26)
Aberrant activation of the PI3K-Akt-mTOR signaling pathway has been observed in human tumors and tumor cell lines, indicating that these protein kinases may be attractive therapeutic targets for treating cancer. Optimization of advanced lead 1 culminated in the discovery of clinical development candidate 8h, GDC-0349, a potent and selective ATP-competitive inhibitor of mTOR. GDC-0349 demonstrates pathway modulation and dose-dependent efficacy in mouse xenograft cancer models.